Imatinib stimulates prostaglandin E 2 and attenuates cytokine release via EP4 receptor activation
To the Editor:
Imatinib is a highly efficacious therapy for leukemias that are characterized by the presence of the Philadelphia chromosome, a reciprocal translocation that fuses the genes encoding breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog (ABL) resulting in the expression of the constitutively active protein kinase BCR-ABL. In addition, imatinib was shown to affect immune responses; for instance, beneficial effects have been described in rheumatoid arthritis 1 and asthma. 2 In human peripheral blood monocytes and in macrophages, imatinib inhibits LPS-induced production of TNF-a, IL-6, and IL-8, via inhibition of nuclear factor kappa B (NF-kB). 3 Because imatinib shows anti-inflammatory and immunomodulatory effects, we were interested in its effect on prostanoid synthesis, especially on prostaglandin (PG)E 2 . Prostaglandins (PGs) and thromboxane A 2 (TXA 2 ) are formed from arachidonic acid, which is released by cytosolic phospholipase c A 2 from membrane phospholipids. Arachidonic acid is metabolized by cyclooxygenases to the unstable intermediate PGH 2 , which is further converted by the respective terminal synthases to PGE 2 , PGI 2 , PGD 2 , PGF 2a , and TXA 2 . PGE 2 is one of the most abundant PGs and exerts its effects by binding to 4 different G protein-coupled receptors (EP1-EP4), which show tissuespecific distribution. PGE 2 was shown to inhibit immune responses mainly via EP4 activation, by curbing cytokine and chemokine expression and promoting a shift of the T H 1 to a T H 2 response, although the EP2 receptor has similar and redundant roles. 4 Thus, we hypothesized that the inhibitory effect of imatinib on proinflammatory cytokines might be mediated by PGE 2 via EP4 receptor activation. The study was approved by the Ethics Committee of the Medical University of Graz to withdraw blood of healthy donors (17-291 ex 05/06) and from patients with chronic myeloid leukemia in complete remission, receiving imatinib (28-590 ex 15/16), after signing informed consent (for patients' data, see Table E1 and Fig E1 in this article's Online Repository at www.jacionline.org; also see this article's Methods section in the Online Repository at www.jacionline.org).
First, we investigated the effect of imatinib in vitro. In adherent human monocytes treated with LPS (10 ng/mL) and further incubated for 20 hours, we found that imatinib caused a significant inhibition of TNF-a that was paralleled by a pronounced (5-10-fold) increase in PGE 2 levels and interestingly an inhibition of TXA 2 , measured as its stable metabolite TXB 2 (Fig 1, A-C) . Pretreatment with diclofenac (1 mM), which totally inhibited PGE 2 synthesis, and the selective EP4 receptor antagonist ONO-AE3 208 (0.3 mM) counteracted the inhibitory effect of imatinib on TNF-a release, underscoring that this effect is indeed mediated by PGE 2 -induced EP4 receptor activation (Fig 1, G and H) , whereas antagonism of the EP2 as well as EP1 and EP3 receptors had no effect (see Fig E2 in this article's Online Repository at www.jacionline.org). This line of reasoning is further strengthened by the fact that the imatinib-induced increase in PGE 2 precedes the inhibition of TNF-a formation (Fig 1, D-F) . The same results were obtained in human monocyte-derived macrophages and human whole blood (see Figs E3 and E4 in this article's Online Repository at www.jacionline.org). Most importantly, we observed the same effects also after treatment with another BCR-ABL inhibitor, nilotinib (see Figs E3-E5 in this article's Online Repository at www.jacionline.org).
In addition, we could prove that the inhibitory effect of imatinib on LPS-stimulated (100 ng/mL) NF-kB activation is dependent on PGE 2 and EP4 receptor activation, as shown in the human macrophage cell line U937 containing an NF-kB-GFP reporter cassette 5 (Fig 1, I ). This observation further corroborates the hypothesis that PGE 2 via EP4 receptor activation inhibits NF-kB, which leads to reduced cytokine production. Data in the Online Repository show that upstream kinases were not involved in the TNF-a inhibition by imatinib and thus further support the notion of an essential mediator role of PGE 2 and EP4 (see Fig E6 in this article's Online Repository at www.jacionline.org). In washed platelet preparations and platelet microsomes we provide evidence that imatinib and nilotinib inhibit arachidonic acid-induced thromboxane synthase (or in case of microsomes PGH 2 ); however, because accumulating PGH 2 acts on thromboxane receptors, platelet aggregation is not affected (see data in this article's Online Repository at www.jacionline.org; also see Fig E7 in this article's Online Repository at www.jacionline.org).
To prove that our in vitro findings can be translated to an in vivo setting, that is, to patients who receive imatinib, blood was drawn from 19 patients with chronic myeloid leukemia (8 females/11 males; median age, 59 years; interquartile range, 14) who were in complete remission under imatinib treatment (400 mg/d) and from 19 matched healthy controls (8 females/11 males; median age, 60 years; interquartile range, 10).
Whole blood was treated with vehicle or stimulated with LPS (10 mg/mL) for 4 hours. Patients treated with imatinib had increased levels of PGE 2 and decreased levels of TXB 2 as compared with healthy controls, although total prostanoid levels did not differ. This was obvious with regard to both baseline generation of prostanoids (vehicle treatment; Fig 2, A) , and the response to LPS stimulation (Fig 2, B) . In addition to PGE 2 , we found that PGD 2 and PGF 2a levels were increased, supporting the hypothesis that inhibition of thromboxane synthase leads to redirection of PGH 2 to other terminal PG synthases. In agreement with our in vitro data we also found that the increase in the inflammatory cytokines TNF-a, IL1-b, and IL-6 and the chemokine IL-8 in LPS-stimulated blood of patients was less pronounced as compared with the cytokine response to LPS in healthy controls (Fig 2, C) . Furthermore, we observed that treatment of patients with imatinib, without influencing total prostanoid levels, shifted prostanoid distribution toward higher and incubated for 20 hours. A-H, N 5 6 to 11; I, N 5 3 to 6; values were calculated as percent of LPS stimulation alone, and are shown as mean 1 SEM. A-C, G, and H, Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Dunnett test; (D-F) with 2-way ANOVA for repeated measurements followed by Sidak multiple comparison test; and (I) with 1-way ANOVA for repeated measurements followed by Tukey multiple comparison test. *P < .05, **P < .01, and ***P < .001 as compared with vehicle, #P < .05 and ##P < .01 as compared with imatinib alone. PGE 2 , PGD 2 , and PGF 2a and lower TXB 2 levels both under unstimulated and LPS-stimulated conditions (Fig 2, F) . In addition, we found a strong inverse correlation between TXB 2 and PGE 2 levels (Fig 2, D and E) .
Our results show for the first time that imatinib causes a pronounced increase in PGE 2 , both in vitro and in vivo. Interestingly, imatinib was shown to ameliorate LPS-induced lung injury by attenuating endothelial barrier dysfunction, which was attributed to inhibition of Abl-related kinase, Arg. 3 Imatinib causes a downregulation of inflammatory cytokines, inflammatory cell infiltration, edema formation, and reactive oxygen species production.
3 Likewise, PGE 2 plays a prominent protective role in the airways; for example, it inhibits LPS-induced lung injury, and enhances microvascular barrier function by activation of the EP4 receptor, thereby ameliorating LPS-induced pulmonary inflammation. 6 Imatinib also ameliorates airway hyperresponsiveness, eosinophilic inflammation, and airway remodeling in murine models of chronic asthma, 7 effects that are also described for PGE 2 . 4 In patients with severe asthma, imatinib, albeit showing no effect on tissue eosinophilia and tissue remodeling, improved airway hyperresponsivness, which was attributed to inhibition of KIT, 2 which is essential for development, survival, and degranulation of mast cells. PGE 2 was also shown to counteract mast cell-mediated bronchoconstiction. 8 Therefore, increased levels of PGE 2 may contribute to the beneficial effects of imatinib in lung conditions.
In conclusion, our data provide indirect evidence that imatinib causes pronounced inhibition of thromboxane synthase, thereby redirecting PGH 2 toward increased PGE 2 synthesis. PGE 2 in turn activates the EP4 receptor and inhibits NF-kB activation and cytokine release. Given that various chronic inflammatory conditions could possibly benefit from increased PGE 2 levels, the potential of already registered drugs that are capable of enhancing PGE 2 levels along with other anti-inflammatory effects is intriguing. Because chronic inflammation is also known to promote leukemogenesis, 9 the PGE 2 mediated anti-inflammatory effects of BCR-ABL inhibitors may add to their therapeutic potential in leukemia. independent experiments. Statistical analysis was performed with Mann-Whitney test. *P < .05, **P < .01, and ***P < .001. In D and E, the levels of TXB 2 and PGE 2 , expressed as % of total prostanoid content, were correlated with each other using linear regression analysis and panel F shows the respective proportions.
Yannick Schreiber, BSc Human primary immunodeficiency caused by expression of a kinase-dead p110d mutant
To the Editor: Human class IA phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of inactive phosphatitdylinositol-4,5-biphosphonate (PIP 2 ) to biologically active phosphatitdylinositol-3,4,5-trisphonate (PIP 3 ), leading to signaling that regulates cell growth, survival, and metabolism. 1 Three catalytic subunits (p110a, p110b, and p110d) heterodimerize with 1 of 5 regulatory subunits. 1 The importance of the p110d
in host immunity has been demonstrated by gain-of-function p110d mutants, resulting in Activated Protein Kinase Delta Syndrome, and much more recently, human deficiency of p110d. [2] [3] [4] Here, we report an immunodeficiency due to a kinase-dead PI3Kd mutant, illustrating the importance of p110d catalytic activity in adaptive immunity.
The patient was the son of consanguineous Pakistani parents, whose other son died at age 6 months because of sepsis. The patient received the attenuated BCG, polio, and measles vaccines without sequelae and was healthy until age 6 years, when he presented with chronic diarrhea and polyarticular arthritis affecting his knees and ankles. He was empirically treated with steroids for 2 months, leading to complete resolution of his symptoms. Over the subsequent 5 years, he had episodes of colitis treated with prednisone, sulfasalazine, and methotrexate for presumed inflammatory bowel disease. Because of worsening colitis, he underwent an upper endoscopy and colonoscopy that revealed candida esophagitis as well as increased intraepithelial lymphocytes and moderate villous blunting in the duodenum. His laboratory evaluation was notable for leukocytosis, neutrophilia, mild monocytosis, and thrombocytosis (Table I) . He had normal numbers of T, B, and natural killer cells and normal percentages of T-and B-cell subsets. His serum levels of IgG and IgA were decreased. Ca 21 flux in response to anti-CD3 crosslinking on T cells was decreased (Fig 1, A) , although proliferation to anti-CD31CD28 stimulation was robust (Table I) . Wholeexome sequencing of the patient revealed a novel homozygous frameshift mutation in PIK3CD (c.2558_2559delAT; Boldface values are outside the normal ranges listed in parentheses.
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METHODS Chemicals
All laboratory reagents were from Sigma (Vienna, Austria), unless specified. The EP4 receptor antagonist ONO AE3-208, ONO 8711, imatinib mesylate, and nilotinib were from Cayman Chemicals (Ann Arbor, Mich). Imatinib mesylate and nilotinib were dissolved in dimethyl sulfoxide and further diluted in PBS to a final concentration of the solvent less than 0.1%.
Preparation of adherent monocytes
Blood was obtained from nonatopic volunteers, who were not taking any medication, according to a protocol approved by the Ethics Committee of the Medical University of Graz (17-291 ex 05/06) after informed consent was provided. Before blood sampling all donors signed an informed consent form. Citrated blood (40 mL) was centrifuged at 300g for 20 minutes at room temperature to remove platelet-rich plasma. Erythrocytes were removed by dextran sedimentation. PBMCs (containing monocytes and lymphocytes), were isolated by Histopaque gradient centrifugation, and washed with PBS containing 5.5 mM glucose and 2.7 mM KCl. Thereafter, cells were resuspended in RPMI 164 supplemented with penicillin (100 U/mL), streptomycin (100 U/mL), glutamine (20 mM), nonessential amino acids, HEPES 0.05 mol, and sodium pyruvate 10 mM (all obtained from Gibco, Thermo Fisher Scientific, Vienna, Austria); 0.5 3 10 6 mononuclear cells/0.5 mL were placed in 24-well plates and 25 mL of human AB serum was added. After 120 minutes of incubation at 37 o C (5% CO 2 ), the nonadherent cells (about 85% of the original mononuclear cells) were removed by aspiration and the plate was washed 3 times with 500 mL PBS. The adherent monocytes were cultured in 1 mL supplemented RPMI 1640 medium at 37 o C (5% CO 2 ).
Preparation of monocyte-derived macrophages
Monocytes were isolated from PBMCs by magnetic separation using Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). Isolated monocytes were seeded at a density of 5 3 10 5 monocytes/mL in 24-well culture plates in RPMI 1640 differentiation medium containing 10% FBS, penicillin (100 U/mL), streptomycin (100 U/mL), and 50 ng/mL M-CSF (Pepro Tech, Vienna, Austria). The medium was changed every third day and after 8 days the medium was replaced by RPMI 1640 with 0.5% FBS overnight before stimulation.
Experimental protocol
Adherent monocytes and macrophages isolated from the blood of healthy donors (isolation and culture conditions as described above) were exposed to vehicle or endotoxin (LPS, Escherichia coli serotype 055:B5) 10 ng/mL for adherent monocytes or 1 mg/mL for monocyte-derived macrophages, and incubated at 37 o C for indicated time periods. Thereafter, the supernatants were collected for radioimmunological determination of PGE 2 , and ELISA for TNF-a and TXB 2 (the stable hydrolysis product of TXA 2 ), and cell viability was determined. In additional experiments, PGs were detected by mass spectrometry. Imatinib and nilotinib or furegrelate were added 20 minutes before LPS, whereas pretreatment with drugs, such as the p38 MAPK inhibitor SB202190, the MEK1/2 inhibitor PD184161, as well as the JNK inhibitor SP600125, the PI3K inhibitor LY294002, the cyclooxygenase inhibitor diclofenac, or the EP4 antagonist ONO AE3-208, started 20 minutes before the addition of imatinib and nilotinib.
Whole blood assay
Aliquots (0.5 mL) of blood samples containing 10 IU/mL sodium heparin were incubated in polystyrene tubes. Imatinib, nilotinib, or vehicle was added 20 minutes before addition of LPS (10 mg/mL) E1 and incubation at 37 o C lasted for 4 hours. Concentrations of nilotinib and imatinib in this assay were chosen with regard to plasma concentrations in patients. E2-E4 Thereafter, blood was centrifuged at 2000g for 10 minutes and PGE 2 , TXB 2 , and TNF-a were determined in plasma.
For experiments involving whole blood from patients receiving imatinib for the treatment of chronic myelogenous leukemia, assays were performed as described above with minor modifications. Aliquots of 2.5 mL of heparinized whole blood from patients or age-and sex-matched controls were incubated with vehicle or LPS (10 mg/mL) for 4 hours at 378C. Blood was centrifuged, plasma was frozen at 2808C, and analyzed for eicosanoids by means of mass spectrometry, and for various cytokines by multiplex ELISA (BD Biosciences).
Radioimmunoassay and ELISA
Immunoreactive PGE 2 was determined as described previously. E5 TNF-a and TXB 2 were determined using commercially available ELISA kits (PeproTech, Rocky Hill, NJ, and Cayman, respectively); other cytokines were determined by multiplex ELISA (Human 13-Plex Human ProcartaPlex Panel 2, Thermo Fisher Scientific) according to the instructions.
Nano-LC tandem mass spectrometry
Prostanoids were quantified as described previously. E6 In brief, 200 mL supernatant or plasma was spiked with the isotopically labeled internal standards and extracted using ethyl acetate. The chromatographic separation of the analytes was carried out using a chiral column Lux Amylose-2 (150 3 2 mm inner diameter, 3 mm) coupled to a Synergi Hydro-RP column (150 3 2 mm inner diameter, 4-mm; both from Phenomenex, Aschaffenburg, Germany) under gradient conditions. Water and acetonitrile, both containing 0.1% formic acid, were used as mobile phases and sample run time was 22 minutes. The MS/MS system consisted of a hybrid triple quadrupole-ion trap mass spectrometer QTrap 5500 (Sciex, Darmstadt, Germany) equipped with a Turbo-V-source operating in the negative electrospray ionisation mode. Analysis was done in the Multiple Reaction Monitoring mode with a dwell time of 50 ms for all analytes. Data were acquired using Analyst Software V 1.6 and quantified with MultiQuant Software V 3.0 (both Sciex, Darmstadt, Germany), using the internal standard method (isotope dilution mass spectrometry).
NF-kB activation
U937T cells containing NF-kB-GFP reporter cassette E7 were kindly provided by H. Strobl (Medical University of Graz). U937T cells were maintained in RPMI 1640 with stable glutamine culture medium (PAA Laboratories) containing 10% FCS and 1 3 Pen/Strep (PAA Laboratories). Cells were seeded at a density of 3 3 10 5 cells/well in 24-well plates and treated with vehicle, imatinib, or nilotinib 20 minutes before stimulation with LPS (100 ng/mL). Twenty hours later cells were harvested and NF-kB activation was measured by flow cytometry as an increase in GFP fluorescence (FacsCalibur, BD Biosciences, Schwechat, Austria). Pretreatment with diclofenac (1 mM) or ONO-AE3 208 (300 nM) was started 20 minutes before addition of imatinib or nilotinib.
Washed platelet aggregation
Aggregation was measured as the increase in light transmission for 6 minutes starting with the addition of proaggregatory stimuli, arachidonic acid (10 mM), or PGH 2 (12 mM). Furegrelate, imatinib, or nilotinib was added 10 minutes before stimulation. In additional experiments platelets were pretreated with acetylsalicylic acid (100 mM) 15 minutes before stimulation. Data were expressed as percent of maximum light transmission, with nonstimulated washed platelets being 0% and Tyrode buffer 100%. At the end of the stimulation period, the platelet suspension was rapidly transferred into Eppendorf tubes and centrifuged at 12,000g for 2 minutes. The supernatant was stored at 280 8C.
centrifuged at 2000g at room temperature for 15 minutes without breaks to pellet platelets. Platelets were resuspended in 50 mM Tris-HCl (pH 5 7.5) and sonicated 3 times for 20 seconds on ice. Thereafter, the resulting suspension was centrifuged at 8000g for 15 minutes at 48C and the supernatant was centrifuged at 100,000g for 60 minutes at 48C, the pellet was resuspended in 1.5 mL of 50 mM Tris-HCl, and frozen at 2808 C.
For thromboxane synthase activity assays, the protein concentrations were adjusted to 150 mg protein/mL and microsomes were preincubated with indicated substances for 10 minutes and then 12 mM PGH 2 was added to start the reaction. After 2 minutes at room temperature, samples were snap frozen on liquid nitrogen and stored at 2808C until determination of TXB 2 concentration.
Data evaluation and statistical analysis
Within each experiment, samples obtained from 1 individual donor were assayed in duplicates for immunoreactive PGE 2 , TXB 2 , and TNF-a. The resulting average was used to calculate means 6 SEM of n independent determinations. To determine the effect of drug treatment, data are either given as absolute values or were calculated as percent of control (LPS stimulation or vehicle treatment alone) and expressed as means 1 SEM. Statistical analysis was calculated with GraphPad Prism 7.0a (GraphPad Software, Inc, La Jolla, Calif) using 1-way ANOVA for repeated measurements or 2-sided Student t test when appropriate; multiple comparisons were done with Tukey or Dunnett post test. For time course experiments, 2-way ANOVA for repeated measurements and Sidak multiple comparison test values was calculated. A P value of less than .05 was considered as significant.
RESULTS
The MAPK, MEK1/2, ERK, JNK, and PI3K are not involved in the effect of imatinib and nilotinib on PGE 2 and TNF-a release
The p38 MAPK inhibitor SB202190 (2 mM), the MEK1/2 inhibitor PD184161 (1 mM), as well as the JNK inhibitor SP600125 (10 mM) and the PI3K inhibitor LY294002 (20 mM) alone all caused a pronounced inhibition of PGE 2 release from LPS-stimulated (10 ng/mL) adherent monocytes as compared with vehicle treatment (Fig E6, A) . The imatinib-and nilotinib-induced increase in PGE 2 release was still evident; however, in the presence of MEK1/2 and PI3K inhibitors, very low amounts were released (Fig E6, A) . TNF-a release was significantly reduced by treatment with SB202190, PD184161, and SP600125, but not LY294002. The inhibitory effect of imatinib and nilotinib on TNF-a release seemed to depend on the amount of PGE 2 that was still released in the presence of inhibitors (Fig E6, B) . In PD184161-and LY294002-treated samples, the inhibitory effect of imatinib and nilotinib on TNF-a release was abrogated ( Fig E6, B) ; however, when exogenous PGE 2 (10 ng/mL) was added, the inhibitory effect was restored (Fig E6, C) .
Imatinib and nilotinib inhibit TXB 2 synthesis in platelets and platelet microsomes, but do not affect aggregation in washed platelets
Because we found a decrease in TXB 2 in imatiniband nilotinib-treated adherent human monocytes (Fig 1, C;   Fig E5, C) , we next investigated this effect in washed human platelets. In platelets, arachidonic acid stimulation leads mainly to formation of TXA 2 via thromboxane synthase, which subsequently promotes platelet activation and aggregation. Arachidonic acid (10 mM) stimulation caused platelet aggregation and TXB 2 formation. Imatinib (1 mM), nilotinib (0.05 mM), and the thromboxane synthase inhibitor furegrelate (0.3-10 mM) significantly inhibited TXB 2 release (Fig E7, A) without showing an effect on platelet aggregation (Fig E7, B) . Inhibition of TXB 2 formation by these compounds was also observed in human platelet microsomes, where the thromboxane synthase is located, E9 after addition of PGH 2 (12 mM; Fig E7, E) . However, both the arachidonic acid-induced aggregation and TXB 2 release were abolished after pretreatment of platelets with acetylsalicylic acid (100 mM, data not shown), indirectly suggesting that inhibition of thromboxane synthase leads to accumulation of PGH 2 . Because it is well known that PGH 2 itself causes platelet aggregation by activation of the TP-receptor, E10 we stimulated aggregation of washed platelets with PGH 2 (12 mM), which was accompanied by a pronounced increase in TXB 2 (Fig E7, C) . As expected, neither imatinib nor nilotinib or furegrelate had an effect on aggregation (Fig E7, D) while TXB 2 release was abrogated. 
FIG E2.
The inhibition of LPS-induced TNF-a release in monocytes by imatinib is not affected by EP1, EP2, or EP3 receptor antagonism. Monocytes were pretreated with the EP1 antagonist ONO8711 (1 mM), the EP2 antagonist PF04418948 (1 mM), or the EP1, EP2, and EP3 antagonist AH6809 (10 mM) 20 minutes before addition of imatinib (1 mM) followed by addition of LPS (10 ng/mL) and incubation for another 20 hours. Thereafter, the concentrations of (A) TNF-a and (B) PGE 2 were determined in the supernatants. All experiments were done in duplicate. Values were calculated as percent of LPS stimulation alone, and are shown as mean 1 SEM of 6 independent experiments. Statistical analysis was performed with 1-way ANOVA followed by Tukey multiple comparison test.
FIG E3.
The inhibition of TNF-a release by imatinib and nilotinib depends on PGE 2 release and EP4 receptor activation in monocyte-derived macrophages. Cells were pretreated with diclofenac (diclo, 1 mM) or the EP4 antagonist ONO AE3-208 (0.3 mM), 20 minutes before addition of imatinib (1 mM) or nilotinib (0.05 mM), followed by addition of LPS (10 ng/mL) and incubation for another 20 hours. Thereafter, the concentrations of (A) TNF-a and (B) PGE 2 were determined in the supernatants. All experiments were done in duplicate. Values were calculated as percent of LPS stimulation alone, and are shown as mean 1 SEM of 6 independent experiments. Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Tukey multiple comparison test. *P < .05, **P < .01, and ***P < .001 as compared with LPS stitmulation. #P < .05 as compared with imatinib or nilotinib treatment alone.
FIG E4.
Imatinib and nilotinib concentration-dependently increase PGE 2 and inhibit TXB 2 in human whole blood; the inhibition of TNF-a release depends on PGE 2 release and EP4 receptor activation. Whole blood was treated with vehicle (veh) or with (A and C) imatinib or (B and D) nilotinib at the indicated concentrations 20 minutes before stimulation with LPS (10 mg/mL) for 4 hours. In E and F, whole blood was treated with diclofenac (diclo, 1 mM) or the EP4 antagonist ONO AE3-208 (0.3 mM), 20 minutes before addition of imatinib or nilotinib at the indicated concentrations, followed 20 minutes later by addition of LPS (10 mg/mL) and incubation for 4 hours. Thereafter, the concentrations of (Fig E4, A, B , and F) PGE 2 , (Fig E4, C, D , and E), TNF-a, and (G and H) TXB 2 were determined in plasma. Values are calculated as percent of vehicle (LPS treatment) and shown as mean 1 SEM of 8 to 9 independent experiments. ND, Not detectable. Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Dunnett test; *P < .05, **P < .01, and ***P < .001 as compared with vehicle stimulation.
FIG E5.
Nilotinib concentration-and time-dependently promotes PGE 2 biosynthesis via thromboxane synthase inhibition and abrogates LPS-induced TNF-a release through PGE 2 and EP4 receptor activation. A-C, Monocytes were pretreated with vehicle (veh) or nilotinib with the indicated concentrations, before cells were stimulated with LPS (10 ng/mL) for 20 hours. D and E, In timecourse experiments, monocytes were treated with vehicle or nilotinib (0.05 mM) before stimulation with LPS and incubated for the indicated time points. G and H, Monocytes were pretreated with vehicle, diclofenac (diclo, 1 mM), or the EP4 antagonist ONO AE3-208 (0.3 mM) before addition of nilotinib, followed by addition of LPS (10 ng/mL) for another 20 hours. (Fig E5, A, D , and G) TNF-a, (Fig E5, B, E , and H) PGE 2 , and ( Fig E5, C and F ) TXB 2 were determined in the supernatants. N 5 6 to 11; values were calculated as percent of LPS stimulation alone, and are shown as mean 1 SEM. A-C, G, and H, Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Dunnett test. *P < .05, **P < .01, ***P < .001. D-F, Timecourse experiments were analyzed by 2-way ANOVA for repeated measurements followed by Sidak multiple comparison test. *P < .05, **P < .01, ***P < .001.
FIG E7.
Imatinib and nilotinib inhibit arachidonic acid (AA) and PGH 2 induced TXB 2 release in washed platelets and platelet microsomes, but have no effect on aggregation. Washed platelets or platelet microsomes were pretreated with vehicle (veh), imatinib (imat; 1 mM), nilotinib (nilo; 0.05 mM), or furegrelate (furegrelat; indicated concentrations, or in case of microsomes 0.3 mM) for 10 minutes. Thereafter, platelets or microsomes were stimulated with (A and B) AA (10 mM) or (C-E) PGH 2 (12 mM) and (Fig E7, B and D ) aggregation was measured as described in the Methods section. (Fig E7, A and C) TXB 2 was determined in the platelet suspension at the end of the aggregation experiment (Fig E7, E) and in the microsome suspension. F and G, Representative recordings of aggregation. Data are shown ( Fig E7, A and C) as % of vehicle, (Fig E7, E) as ng/mg protein/min, or ( Fig E7, B and D) as percent of induced aggregation as mean 1 SEM of 6 to 9 independent experiments. Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Dunnett test for comparison with vehicle. *P < .05, **P < .01, ***P < .001. 
